세계의 차세대 당뇨병 치료 및 약물전달 시장

Global Next Generation Diabetes Therapy and Drug Delivery Market to Reach US$34.1 Billion by 2030

The global market for Next Generation Diabetes Therapy and Drug Delivery estimated at US$24.0 Billion in the year 2024, is expected to reach US$34.1 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Inhalable Insulin, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$13.9 Billion by the end of the analysis period. Growth in the Oral Insulin segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.3 Billion While China is Forecast to Grow at 6.0% CAGR

The Next Generation Diabetes Therapy and Drug Delivery market in the U.S. is estimated at US$6.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.5 Billion by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.4% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Next Generation Diabetes Therapy and Drug Delivery Market - Key Trends & Drivers Summarized

Why Is the Landscape of Diabetes Therapy Undergoing a Transformation?

Next generation diabetes therapies are transforming how patients manage both Type 1 and Type 2 diabetes by offering more targeted, efficient, and user-friendly solutions. Traditional treatment approaches often involve multiple daily insulin injections or oral hypoglycemics with limited personalization. In contrast, the emerging therapeutic landscape focuses on precision delivery, patient-centric designs, and improved metabolic outcomes. Innovations are addressing persistent challenges such as hypoglycemia risk, therapy adherence, and glucose variability.

The growing global diabetes burden, coupled with long-term complications such as cardiovascular disease, neuropathy, and renal impairment, is intensifying demand for advanced therapies. Early intervention models, emphasis on glycemic control, and the shift toward home-based care are encouraging the adoption of next-generation systems. Patients are increasingly opting for integrated treatment solutions that combine convenience, real-time monitoring, and minimal invasiveness.

How Are Novel Drug Classes and Delivery Mechanisms Redefining Treatment Pathways?

Several new drug classes are expanding therapeutic options beyond insulin and metformin. GLP-1 receptor agonists, SGLT2 inhibitors, and dual agonists are now integral to Type 2 diabetes care due to their benefits in weight reduction, cardiovascular safety, and kidney protection. These agents are being delivered via weekly injectables, autoinjectors, and sustained-release implants that improve patient compliance and minimize side effects.

Delivery mechanisms are evolving rapidly, with insulin pumps, patch pumps, and smart pens gaining traction. Closed-loop systems, often termed artificial pancreas, combine continuous glucose monitoring with automated insulin delivery, allowing dynamic, algorithm-driven dosing adjustments. Microneedle arrays, inhalable insulin formulations, and oral peptide drugs are under development to eliminate injection-related barriers. These delivery innovations are enhancing therapeutic precision while promoting comfort and long-term adherence.

What Broader Healthcare Trends Are Supporting Technology Adoption in Diabetes Management?

Digital health integration is a major enabler of next-generation diabetes therapy. Connected insulin pens, mobile apps, and cloud-based platforms allow data sharing, trend tracking, and remote consultation. Patients and clinicians can now access real-time data for dose optimization and lifestyle adjustments, enhancing personalized care. Interoperability between monitoring devices and insulin delivery systems is improving usability, particularly for pediatric and elderly populations.

Healthcare systems are gradually adopting value-based care models, which emphasize outcome-driven interventions. This shift is encouraging use of therapies and devices that offer long-term benefits such as reduced hospitalization, improved quality of life, and prevention of complications. Growth in telemedicine and home health services is further supporting decentralization of diabetes care. Insurance reimbursement for advanced therapies and inclusion in national diabetes programs are helping accelerate adoption, especially in developed markets.

What Factors Are Driving Growth in the Next Generation Diabetes Therapy and Drug Delivery Market?

Growth in the next generation diabetes therapy and drug delivery market is driven by several factors. Rising global prevalence of diabetes is creating sustained need for innovative and efficient treatment models. Introduction of novel drug classes with extended half-lives and cardiometabolic benefits is reshaping pharmacological strategies. Advancements in smart delivery systems, including closed-loop pumps and wearable injectors, are improving control and patient autonomy. Digital integration and remote care enablement are enhancing treatment personalization and clinical oversight. Expansion of reimbursement coverage and regulatory support for integrated solutions are facilitating faster market entry and broader access. These trends are collectively redefining diabetes management, driving demand for advanced therapies and next-generation delivery technologies.

SCOPE OF STUDY:

The report analyzes the Next Generation Diabetes Therapy and Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas); Indication (Type 1 Diabetes, Type 2 Diabetes); End-Use (Diagnostics / Clinics End-Use, Intensive Care Units End-Use, Home Healthcare End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

• Abbott Laboratories
• Beta Bionics, Inc.
• Camurus AB
• Dexcom, Inc.
• Eli Lilly and Company
• Enteris BioPharma
• GlySens Incorporated
• Johnson & Johnson
• MannKind Corporation
• Medtech S.A.
• Medtronic plc
• Nemaura Medical Inc.
• Novo Nordisk A/S
• Oramed Pharmaceuticals Inc.
• Relmada Therapeutics
• Roche Holding AG
• Sanofi S.A.
• Senseonics Holding, Inc.
• Tandem Diabetes Care, Inc.
• Ypsomed AG
• Zosano Pharma Corp.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Next Generation Diabetes Therapy and Drug Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Diabetes Prevalence Drives Demand for Innovative Therapy and Delivery Solutions
  • Shift Toward Patient-Centric Care Models Propels Adoption of Personalized Diabetes Treatments
  • Advancements in Continuous Glucose Monitoring (CGM) Systems Enhance Insulin Delivery Accuracy
  • Integration of AI and Data Analytics into Drug Delivery Devices Strengthens Disease Management
  • Growing Use of Smart Insulin Pens and Connected Devices Supports Real-Time Dose Optimization
  • Development of Non-Invasive Insulin Delivery Systems Expands Market Accessibility
  • Emergence of Dual and Triple Agonists for Type 2 Diabetes Therapy Accelerates Pipeline Innovation
  • Increasing Preference for Oral GLP-1 Receptor Agonists Enhances Patient Compliance
  • Focus on Minimally Invasive Technologies Spurs Growth in Microneedle Patch Development
  • Expansion of Closed-Loop Insulin Delivery Systems Throws the Spotlight on Automated Diabetes Care
  • Patient Demand for Discreet, Portable Delivery Systems Drives Design Evolution in Wearable Injectors
  • Investment in Regenerative Therapies Including Stem Cell-Based Interventions Fuels Long-Term Research
  • Rising Burden of Diabetes in Low and Middle-Income Countries Expands Scope for Cost-Effective Delivery Options
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Next Generation Diabetes Therapy and Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Inhalable Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Inhalable Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Oral Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Oral Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Insulin Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Insulin Patches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for CGM Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for CGM Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Artificial Pancreas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Artificial Pancreas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Home Healthcare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Home Healthcare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostics / Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Diagnostics / Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 18: World Recent Past, Current & Future Analysis for Intensive Care Units End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 19: World 6-Year Perspective for Intensive Care Units End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Type 1 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World 6-Year Perspective for Type 1 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 22: World Recent Past, Current & Future Analysis for Type 2 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 23: World 6-Year Perspective for Type 2 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 24: USA Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 25: USA 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 27: USA 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 28: USA Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 29: USA 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• CANADA
  • TABLE 30: Canada Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 31: Canada 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: Canada 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 34: Canada Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 35: Canada 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• JAPAN
  • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 36: Japan Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Japan 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Japan 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 40: Japan Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 41: Japan 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• CHINA
  • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 42: China Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 43: China 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: China 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 46: China Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 47: China 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• EUROPE
  • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 48: Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 49: Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 52: Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 53: Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 54: Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 55: Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• FRANCE
  • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: France 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 58: France Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 59: France 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 60: France Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 61: France 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• GERMANY
  • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Germany 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 64: Germany Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Germany 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 66: Germany Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Germany 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Italy 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 70: Italy Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 71: Italy 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 72: Italy Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 73: Italy 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• UNITED KINGDOM
  • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: UK 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 76: UK Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 77: UK 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 78: UK Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 79: UK 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Rest of Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 83: Rest of Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 85: Rest of Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• ASIA-PACIFIC
  • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Asia-Pacific 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 89: Asia-Pacific 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 91: Asia-Pacific 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Rest of World 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
  • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 95: Rest of World 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
  • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 97: Rest of World 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030

IV. COMPETITION